- Biogen Alzheimer’s drug and the battle over dementia treatment of the future CNBC
- Cramer on FDA resignations in connection with approval of Biogen's Alzheimer's drug CNBC Television
- 3 Experts Quit An FDA Panel Over Alzheimer's Drug Approval NPR
- The debate over the FDA-approved Alzheimer’s drug showcases our system’s skewed priorities The Washington Post
- The Alzheimer’s economy: is the new $56,000-a-year drug worth it? Financial Times
- View Full Coverage on Google News
from Top stories - Google News
0 Comments